[Sinovac Reports Unaudited Second Quarter 2016 Financial Results BEIJING, August 23, 2016 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today its unaudited second quarter ended June 30, 2016. Mr. Weidong Yin, Chairman, President and CEO of the Sinovac, commented, “As forecasted on our first quarter earnings call, we experienced a continued] []
[Sinovac Reports Unaudited Second Quarter 2016 Financial Results BEIJING, August 23, 2016 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today its unaudited second quarter ended June 30, 2016. Mr. Weidong Yin, Chairman, President and CEO of the Sinovac, commented, “As forecasted on our first quarter earnings call, we experienced a continued] []
[FORM 10-Q (Mark One) ☒ June 30, 2016 For the quarterly period ended: Or ☐ For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, INC. Maryland 20-8747899 (State or other jurisdiction of incorporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province People’s Republic of China 712046 (Zip code) 011-86-29-33686638 (Former name, former] [CERTIFICATION I, Ronghua Wang, certify that: 1. I have reviewed this Form 10-Q of Biostar Pharmaceuticals, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading] [CERTIFICATION I, Qinghua Liu, certify that: 1. I have reviewed this Form 10-Q of Biostar Pharmaceuticals, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading] [CERTIFICATION OF CHIEF EXECUTIVE OFFICER 1. 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for said period. Ronghua Wang EX-32.1 4 ex32-1.htm EX-32.1] [CERTIFICATION OF CHIEF FINANCIAL OFFICER 1. 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for said period. Qinghua Liu Qinghua Liu Interim Chief Financial Officer (Principal Financial and Accounting Officer) EX-32.2 5 ex32-2.htm EX-32.2]
[FORM 10-Q (Mark One) ☒ June 30, 2016 For the quarterly period ended: Or ☐ For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, INC. Maryland 20-8747899 (State or other jurisdiction of incorporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province People’s Republic of China 712046 (Zip code) 011-86-29-33686638 (Former name, former] [CERTIFICATION I, Ronghua Wang, certify that: 1. I have reviewed this Form 10-Q of Biostar Pharmaceuticals, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading] [CERTIFICATION I, Qinghua Liu, certify that: 1. I have reviewed this Form 10-Q of Biostar Pharmaceuticals, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading] [CERTIFICATION OF CHIEF EXECUTIVE OFFICER 1. 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for said period. Ronghua Wang EX-32.1 4 ex32-1.htm EX-32.1] [CERTIFICATION OF CHIEF FINANCIAL OFFICER 1. 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for said period. Qinghua Liu Qinghua Liu Interim Chief Financial Officer (Principal Financial and Accounting Officer) EX-32.2 5 ex32-2.htm EX-32.2]
[FORM 12b-25 NOTIFICATION OF LATE FILING CUSIP NUMBER: 090678 301 o o o (Check One): x o o For Period Ended: June 30, 2016 o o o o o For the Transition Period Ended: ____________________ Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. If the notification relates to a portion]
[FORM 12b-25 NOTIFICATION OF LATE FILING CUSIP NUMBER: 090678 301 o o o (Check One): x o o For Period Ended: June 30, 2016 o o o o o For the Transition Period Ended: ____________________ Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. If the notification relates to a portion]
[☐ Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer (Do not check if a smaller reporting company) ☒ Smaller reporting company ☐ ☒ APPLICABLE ONLY TO CORPORATE ISSUERS: 2 CHINA PHARMA HOLDINGS, INC. AND SUBSIDIARIES TABLE OF CONTENTS PART I FINANCIAL INFORMATION Page Item 1.] [CERTIFICATION OF OF THE SARBANES-OXLEY ACT OF 2002 I, Zhilin Li certify that: 1. I have reviewed this report on Form 10-Q of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER OF THE SARBANES-OXLEY ACT OF 2002 I, Zhilin Li, certify that: 1. I have reviewed this report on Form 10-Q of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made,] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: August 11, 2016 President and Chief Executive Officer (principal financial officer and principal accounting officer) EX-32.1 4 ex321.htm]
[☐ Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer (Do not check if a smaller reporting company) ☒ Smaller reporting company ☐ ☒ APPLICABLE ONLY TO CORPORATE ISSUERS: 2 CHINA PHARMA HOLDINGS, INC. AND SUBSIDIARIES TABLE OF CONTENTS PART I FINANCIAL INFORMATION Page Item 1.] [CERTIFICATION OF OF THE SARBANES-OXLEY ACT OF 2002 I, Zhilin Li certify that: 1. I have reviewed this report on Form 10-Q of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER OF THE SARBANES-OXLEY ACT OF 2002 I, Zhilin Li, certify that: 1. I have reviewed this report on Form 10-Q of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made,] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: August 11, 2016 President and Chief Executive Officer (principal financial officer and principal accounting officer) EX-32.1 4 ex321.htm]
